A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to-moderate COVID-19 with moderate certainty.

Most COVID-19 Drugs Fall Short, Meta-Analysis Confirms

Japanese drugmaker Shionogi has filed a supplemental application in Japan to broaden the use of its oral antiviral Xocova (ensitrelvir), aiming to include children as young as six who weigh at least 20 kilograms.

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral

Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Treatment of COVID-19 in Pediatric Patients Aged 6 Years and Older.

Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Treatment of COVID-19 in Pediatric Patients Aged 6 Years and Older

The Ministry of Health recommends starting antiviral therapy as early as possible, no later than 7-8 days from the onset of symptoms, which refers to etiotropic treatment (aimed at eliminating the cause of the disease - ed.).

The Ministry of Health clarified the recommendations for the treatment of coronavirus

Shinpoong Pharmaceutical said Tuesday that it received a decision from the European Patent Office (EPO) to grant a patent for Pyramax (pyronaridine phosphate-artesunate), which was approved for treating malaria last Friday.

antiviral news

Press Releases in the global landscape